Search

Your search keyword '"Wörmann, B"' showing total 1,478 results

Search Constraints

Start Over You searched for: Author "Wörmann, B" Remove constraint Author: "Wörmann, B"
1,478 results on '"Wörmann, B"'

Search Results

5. Randomized Comparison of Sequential High-Dose Cytosine Arabinoside and Idarubicin (S-HAI) with or without Chemo-Modulation by Fludarabine in Refractory and Relapsed Acute Myeloid Leukemia

6. Multivariate Analysis of Prognostic Factors in Patients with Refractory and Relapsed Acute Myeloid Leukemia Undergoing Sequential High-Dose Cytosine Arabinoside and Mitoxantrone (S-HAM) Salvage Therapy: Significance of Cytogenetic Abnormalities

10. The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO)

13. Hematopoietic Growth Factors: Supportive and Priming Effects in AML

15. Failure of Fluconazole Prophylaxis to Reduce Mortality During Treatment for Refractory Acute Myeloid Leukemia: Results of a Phase III Multicenter Study

18. Granulocyte Colony-Stimulating Factor Improves the Antileukemic Efficacy of the Sequential High-Dose Cytosine Arabinoside and Mitoxantrone Regimen (S-HAM) in Patients Younger than 60 Years with High-Risk Acute Myeloid Leukemia

19. Superiority of High-Dose over Intermediate-Dose Cytosine Arabinoside (AraC) in the Treatment of Patients with High-Risk Acute Myeloid Leukemia (AML)

21. All-Trans Retinoic Acid (ATRA) Combined with Double Induction Strategy in Acute Promyelocytic Leukemia (APL). Preliminary Results

22. Biologic Determinants for AML Therapy

25. Growth Factors in AML: Updates

26. Fludarabine and Fludarabine, Mitoxantrone, Dexamethasone in the Management of Low-Grade Non-Hodgkin Lymphomas

28. Correlation of Deoxycytidine Deaminase, Thymidine Kinase and Polymerase Alpha Activity and Deoxycytidine Deaminase Gene Expression In Vivo with Clinical Response to TAD-9+GM-CSF Induction Therapy in Acute Myeloid Leukemia

29. Characterization of Normal and Leukemic Lymphohematopoietic Precursor Cells by Three-Color Flow Cytometry and Detection of Clone-Specific Leukemia-Associated T-Cell Receptor δ Rearrangements

33. Preliminary Results of a Placebo-Controlled, Double-Blind Trial Evaluating Sequential HD-AraC/Mitoxantrone Induction Chemotherapy with or Without Granulocyte-Macrophage Colony-Stimulating Factor in Patients with High-Risk Myelodysplastic Syndromes

36. Interleukin-2 Postremission Therapy in Acute Myeloid Leukemia (AML): In Vitro and In Vivo Effects of a Five Day Continuous Infusion of IL-2 on Phenotype and Function of Peripheral Lymphocytes

37. S-HAM Salvage Therapy of Relapsed and Refractory AML Followed by Interleukin 2 Postremission Therapy

39. Hematologic and Therapeutic Effects of High-Dose AraC/Mitoxantrone (HAM) in the Induction Treatment of Patients with Newly Diagnosed AML. A Trial by AML Cooperative Group

40. Fludarabine in Combination with Mitoxantrone and Dexamethasone in Relapsed and Refractory Low-Grade Non-Hodgkin’s Lymphoma

41. Heterogeneity of HRX-FEL Fusion Transcripts in Adult and Pediatric t(4;11) ALL

43. Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia

44. Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia

Catalog

Books, media, physical & digital resources